Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS EXON 2 MUTATION
KRAS EXON 2 MUTATION - Associated Disease
- pancreatic carcinoma
- Source Database
- CIViC Evidence
- Description
- KRAS exon 2 was mutated in 121 of 173 (70%) patients with advanced pancreatic cancer and did not show an association with response to erlotinib treatment.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/916
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/75
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Pancreatic Carcinoma
- Evidence Direction
- Does Not Support
- Drug
- Erlotinib
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 23435671
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Erlotinib | Resitance or Non-Reponse | false |